GrayMatters Health (GMH), a developer of digital self-neuromodulation therapeutics for mental disorders, has closed a $10 million Series A financing round, the company announced Tuesday.
Follow Israel Hayom on Facebook, Twitter, and Instagram
Japan's Otsuka Medical Devices Co., Ltd. (OMD) was the lead investor in this round. In addition to its investment, OMD obtained certain rights with regard to Prism in Japan and other countries in Asia. Additional investors in the Series A round included Joy Ventures, J-Ventures, and J-Impact. Existing GMH investors, Marius Nacht and Joyance Ventures, also participated in the round.
Connecting mental disorders with their underlying brain mechanisms, GMH's Prism product is designed to help patients regain agency over their emotion regulation. Prism is a non-invasive adjunct digital therapeutic that utilizes novel neuroscience-based and brain-mechanism-specific biomarkers. GMH is the first to use machine learning technology to create an Electrical-Finger-Print (EFP) of brain-mechanism-specific biomarkers that are utilized in its proprietary treatment of mental disorders, training patients to employ self neuro-modulation techniques using an interactive audio-visual software.
"GrayMatters is introducing the first digital therapeutic device that directly targets and regulates specific brain biomarkers associated with mental disorders, whereas digitizing existing therapy methods focus on mitigating the resulting symptoms and behaviors," said Oded Kraft, GrayMatters Health co-founder and CEO.
"This funding round will help GrayMatters Health complete its clinical investigation, obtain clearance from regulatory authorities, and launch Prism for PTSD in the United States. It also supports our collaboration with McLean Hospital, the largest psychiatric affiliate of Harvard Medical School and a member of Mass General Brigham. Together we plan to conduct a clinical investigation to determine Prism's efficacy and safety as an adjunct treatment for Major Depressive Disorder (MDD) with anhedonia," Kraft said.
The company plans to evaluate the clinical efficacy and safety of Prism for additional mental disorder indications including MDD, Attention Deficit Hyperactivity Disorder, General Anxiety Disorder, Obsessive Compulsive Disorder, and Borderline Personality Disorder.
